Why Is Bexagliflozin (Brenzavvy) So Hard to Find? [Explained for 2026]

You have a prescription for Brenzavvy — one of the most affordable SGLT2 inhibitors on the market — and your pharmacy says they don't carry it. Sound familiar? You're not alone. Bexagliflozin (brand name Brenzavvy) is FDA-approved for type 2 diabetes and priced far below its competitors, yet many patients spend hours searching before finding a place to fill their prescription.

This guide breaks down exactly why Brenzavvy is so hard to find — and, more importantly, what you can do about it.

What Is Bexagliflozin (Brenzavvy)?

Bexagliflozin, sold under the brand name Brenzavvy, is an SGLT2 inhibitor made by TheracosBio. It was approved by the FDA on January 23, 2023, for adults with type 2 diabetes as an adjunct to diet and exercise.

It works the same way as better-known drugs like Jardiance (empagliflozin) and Farxiga (dapagliflozin): by blocking a protein in the kidneys that normally reabsorbs glucose, causing excess blood sugar to be flushed out through urine. The big difference? Brenzavvy was intentionally priced to be affordable — as low as $47–$50 per month through partner pharmacies like Cost Plus Drugs, compared to $500–$550 per month for Jardiance.

Is Bexagliflozin in Short Supply?

Short answer: No. As of early 2026, Brenzavvy is not listed on the FDA Drug Shortage Database. The challenge is not a manufacturing or supply shortage — it is a distribution and stocking issue.

Most chain pharmacies — CVS, Walgreens, Rite Aid — stock medications based on demand. Brenzavvy is a newer drug from a smaller pharmaceutical company, and without the large marketing budgets of Eli Lilly (Jardiance) or AstraZeneca (Farxiga), it has not built the prescription volume needed to earn shelf space at every corner pharmacy.

5 Real Reasons Brenzavvy Is Hard to Find

1. It uses a direct-to-consumer distribution model.

TheracosBio chose to launch Brenzavvy through direct-to-consumer and online pharmacy channels instead of the traditional wholesale network. Initially, it was only available through Mark Cuban's Cost Plus Drugs online pharmacy. Distribution has expanded to include DiRx, Marley Drug, Publix pharmacies, and independent pharmacies via the IPC network — but most big-chain pharmacies still don't stock it.

2. Most insurance plans don't cover it.

Most Medicare Part D plans and many commercial insurance formularies do not include Brenzavvy. Insurers tend to prefer SGLT2 inhibitors with established track records and broader indications, like Jardiance (which is also approved for heart failure). When insurance doesn't cover Brenzavvy, retail pharmacies have even less reason to keep it in stock.

3. Limited prescriber awareness.

Without a large sales force providing samples to doctors' offices, many prescribers simply aren't aware of Brenzavvy. Fewer prescriptions mean less pharmacy demand, which means less stocking — it's a frustrating cycle for patients who have been prescribed it.

4. Pharmacies prioritize high-demand drugs.

Large chain pharmacies allocate shelf and refrigerator space based on prescription volume and wholesale contracts. With Brenzavvy having lower overall prescription counts than Jardiance or Farxiga, many chains haven't added it to their standard inventory.

5. No major recall or safety issue.

To be clear: the difficulty finding Brenzavvy has nothing to do with safety or a recall. The drug is available — just not through the channels most patients are used to.

Where Can You Actually Get Brenzavvy in 2026?

Here are the best places to fill a Brenzavvy prescription in 2026:

Cost Plus Drugs (costplusdrugs.com) — $49.85/month, ships to most states

DiRx Pharmacy — $47.75/month, online prescription delivery

Marley Drug — $69/month, 90-day supply options available

Publix pharmacies — now stocking Brenzavvy in-store in select regions

Independent pharmacies — via the IPC network (7,000+ member pharmacies nationwide)

The fastest way to find Brenzavvy in stock near you is to use medfinder. medfinder calls pharmacies on your behalf to check which ones can fill your prescription — saving you hours of phone calls. Enter your medication, dose, and location to get started.

What If I Can't Find Brenzavvy Anywhere?

If you've exhausted every option and still can't fill your prescription, talk to your doctor about alternative SGLT2 inhibitors. Jardiance, Farxiga, and Invokana work via the same mechanism and are widely stocked at most pharmacies. They cost more out-of-pocket, but your insurance may cover them — and many manufacturers offer copay savings programs.

Also worth noting: TheracosBio has confirmed that Brenzavvy is available nationwide through its network of partner pharmacies. If your current pharmacy doesn't have it, the medication itself is not in short supply — you just need to find the right pharmacy.

Why Is Brenzavvy So Much Cheaper Than Other SGLT2 Inhibitors?

TheracosBio has stated that their mission is to provide access to new medications for patients with common diseases at appropriate prices. Unlike Eli Lilly and AstraZeneca — which spend heavily on direct-to-consumer advertising and large sales forces — TheracosBio keeps overhead low and passes those savings to patients.

Some pharmacy benefit managers (PBMs) are beginning to recognize this value. Scripius, a PBM owned by Intermountain Health, removed Jardiance from its formularies in 2024 and added Brenzavvy as the preferred SGLT2 inhibitor — citing a cost of roughly $55/month for Brenzavvy versus $550/month for Jardiance.

Bottom Line: Is Brenzavvy Worth the Effort to Find?

Absolutely. For patients whose primary need is affordable glycemic control for type 2 diabetes, Brenzavvy offers the same SGLT2 mechanism as pricier competitors at a fraction of the cost. The search just requires going beyond the usual big-chain pharmacies.

For a step-by-step walkthrough of finding Brenzavvy in stock, see our guide on how to check if a pharmacy has Brenzavvy in stock.